AOD-9604 vs Tesamorelin

AOD-9604: Fat-metabolizing fragment of human growth hormone without growth-promoting effects. Typical dose 250-500 mcg. Tesamorelin: FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity. Typical dose 1000-2000 mcg. Both fall under the Weight Management and Growth Hormone categories.

Stacking AOD-9604 with Tesamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

AOD-9604 is typically dosed: Once daily (SubQ) for Fat loss and body composition. Tesamorelin is typically dosed: Once daily (SubQ) for HIV lipodystrophy (FDA approved); Once daily for Body composition / anti-aging (off-label).

AOD-9604: Not FDA approved as a drug. Granted GRAS status as a food additive in 2014. Tesamorelin: FDA approved. Egrifta (tesamorelin) approved November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta SV (reformulated single-vial) approved 2019.